MaRS Innovation

$10 Million Series A financing in Xagenic

Susanne Staer — Fri, 03 Feb 2012 17:07:21 +0000

Toronto (January 30, 2012) – Xagenic Inc., a start-up company created by University of Toronto Professor Dr. Shana Kelley and… Read More »

Top 100 Hall of Fame welcomes Mary Jo Haddad

Susanne Staer — Thu, 08 Dec 2011 16:46:21 +0000

Mary Jo Haddad, President and CEO of the Hospital for Sick Children and Chair of the Board of Directors of… Read More »

Encycle Investigators Receive CQDM Investment

Susanne Staer — Tue, 06 Dec 2011 19:44:50 +0000

Toronto, December 6th, 2011 – The Quebec Consortium for Drug Discovery (CQDM) is pleased to announce the funding of two… Read More »

Prestigious Award: Board Member Ilse Treurnicht

Susanne Staer — Thu, 01 Dec 2011 20:27:33 +0000

TORONTO (December 1, 2011) – MaRS Discovery District congratulates CEO Dr. Ilse Treurnicht for being recognized as one of Canada’s… Read More »

DLVR Therapeutics Inc. adds MaRS Innovation to investor base

Susanne Staer — Tue, 25 Oct 2011 20:04:52 +0000

TORONTO, Ontario, Canada – October 24, 2011 – DLVR Therapeutics Inc. - a privately-held biotechnology company currently focused on developing oncology therapeutics based on its proprietary high density lipoprotein-like nanoparticle – announced today that the Company has completed its seed round investment bringing the total raised to $2 million in cash and in-kind support.

Interview with Rafi Hofstein: Commercializing Canadian Assets

Susanne Staer — Tue, 11 Oct 2011 16:41:22 +0000

Canadian International Council Video Interview with Rafi Hofstein on commercializing Canadian assets:

Provincial Investment Supports Commercialization of Leading-Edge Molecular Diagnostic Screening Technology

Susanne Staer — Tue, 26 Jul 2011 18:22:55 +0000

Toronto (July 26, 2011) – Xagenic Inc., one of MaRS Innovation’s portfolio investments, was awarded $1-million in funding by Ontario’s Ministry… Read More »

MaRS Innovation and GlaxoSmithKline Announce Strategic Partnership to Accelerate Translational Research in Health Sciences

Susanne Staer — Tue, 31 May 2011 13:06:44 +0000

TORONTO (May 31, 2011) – MaRS Innovation (MI) and GlaxoSmithKline Inc. (GSK) today announced a new development fund — the GSK-MaRS Innovation Fund — that will support and fast-track the commercialization of some of the country’s most promising translational research coming from 16 leading academic health sciences centres, hospitals and universities derived from the MI membership.

York University becomes 17th Member of MaRS Innovation

Susanne Staer — Mon, 09 May 2011 14:00:04 +0000

MaRS Innovation will act as commercialization agent for York’s life sciences and technology discoveries. Relationship to leverage new potential for… Read More »

Launch of Otosim Inc. – MI provides crucial commercialization funding to develop otoscopy training system

Susanne Staer — Mon, 25 Apr 2011 20:13:11 +0000

TORONTO – April 25, 2011 – MaRS Innovation (www.marsinnovation.com) and The Hospital for Sick Children (SickKids, www.sickkids.ca) announced today the launch of OtoSim Inc. (www.otosim.com) to commercialize an otoscopy training system and process developed by two otolaryngologists at SickKids.

The new product, a program and training device, is the first in a series of training systems directed at improving the accuracy of ear examinations, and is part of a growing trend to use simulation-based training in medicine.